Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

The Lancet

Volumn 376, Issue 9738, 2010, Pages 367-387

  Altice, Frederick L ^a,b   Kamarulzaman, Adeeba ^b   Soriano, Vincent V ^c   Schechter, Mauro ^d   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ACAMPROSATE; AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; BENZODIAZEPINE; BUPRENORPHINE; COCAINE; DIDANOSINE; DISULFIRAM; EFAVIRENZ; KETAMINE; LOPINAVIR; METHADONE; METHAMPHETAMINE; NALTREXONE; NICOTINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OPIATE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TIPRANAVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VARENICLINE; ZIDOVUDINE;

ALCOHOL ABUSE; ALCOHOLISM; AMENORRHEA; BACTERIAL INFECTION; CIGARETTE SMOKING; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; CRIMINAL JUSTICE; DEMENTIA; DEPRESSION; DIAPHORESIS; DIZZINESS; DRUG ABUSE; DRUG COST; DRUG DEPENDENCE TREATMENT; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEADACHE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEART ARRHYTHMIA; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION CONTROL; INFLUENZA; INSOMNIA; INTRAVENOUS DRUG ABUSE; LIVER TOXICITY; MENTAL DISEASE; METHADONE TREATMENT; MORTALITY; NAUSEA; OPIATE ADDICTION; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TACHYCARDIA; TOBACCO DEPENDENCE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VIRUS INFECTION; VOMITING;

EID: 77955714260     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60829-X     Document Type: Review

References (166)

1. 3 allows HIV-infected men, but not women, to reach similar mortality rates to those of the general population: a seven-year analysis. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 16-19, 2010. Abstract 527.
2. RD Bruce, FL Altice Clinical care of the HIV-infected drug user Infect Dis Clin North Am 21 2007 149 179
3. TA Partanen, P Vikatmaa, E Tukiainen, M Lepantalo, J Vuola Outcome after injections of crushed tablets in intravenous drug abusers in the Helsinki University Central Hospital Eur J Vasc Endovasc Surg 37 2009 704 711
4. B Brands, J Blake, DC Marsh, B Sproule, R Jeyapalan, S Li The impact of benzodiazepine use on methadone maintenance treatment outcomes J Addict Dis 27 2008 37 48
5. T Kerr, N Fairbairn, M Tyndall Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users Drug Alcohol Depend 87 2007 39 45
6. H Ashton The diagnosis and management of benzodiazepine dependence Curr Opin Psychiatry 18 2005 249 255
7. P Lobmaier, H Kornor, N Kunoe, A Bjorndal Sustained-release naltrexone for opioid dependence Cochrane Database Syst Rev 2 2008 CD006140.
8. M Srisurapanont, N Jarusuraisin Opioid antagonists for alcohol dependence Cochrane Database Syst Rev 1 2005 CD001867.
9. ME Piper, SS Smith, TR Schlam A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies Arch Gen Psychiatry 66 2009 1253 1262
10. SS Smith, DE McCarthy, SJ Japuntich Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics Arch Intern Med 169 2009 2148 2155
11. RD Bruce, TF Kresina, EF McCance-Katz Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users AIDS 24 2010 331 340
12. J Thirthalli, PK Chand The implications of medication development in the treatment of substance use disorders in developing countries Curr Opin Psychiatry 22 2009 274 280
13. J Izenberg, FL Altice Next steps for Ukraine - abolition of HIV registries, implementation of routine HIV testing and expansion of services Addiction 105 2010 569 570
14. L Amato, S Minozzi, M Davoli, S Vecchi, MM Ferri, S Mayet Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification Cochrane Database Syst Rev 4 2008 CD005031.
15. RP Mattick, C Breen, J Kimber, M Davoli Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence Cochrane Database Syst Rev 3 2009 CD002209.
16. JB Murray Effectiveness of methadone maintenance for heroin addiction Psychol Rep 83 1998 295 302
17. L Amato, M Davoli, CA Perucci, M Ferri, F Faggiano, RP Mattick An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research J Subst Abuse Treat 28 2005 321 329
18. P Lobmaier, H Kornor, N Kunoe, A Bjorndal Sustained-release naltrexone for opioid dependence Cochrane Database Syst Rev 2 2008 CD006140.
19. B Spire, GM Lucas, MP Carrieri Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST) Int J Drug Policy 18 2007 262 270
20. N Lintzeris, A Ritter, M Panjari, N Clark, J Kutin, G Bammer Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial Am J Addict 13 suppl 1 2004 S29 S41
21. FL Altice, LE Sullivan, D Smith-Rohrberg, S Basu, S Stancliff, L Eldred The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention Clin Infect Dis 43 suppl 4 2006 S178 S183
22. S Basu, D Smith-Rohrberg, RD Bruce, FL Altice Models for integrating buprenorphine therapy into the primary HIV care setting Clin Infect Dis 42 2006 716 721
23. MP Carrieri, C Leport, C Protopopescu Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase J Acquir Immune Defic Syndr 41 2006 477 485
24. E Durand Changes in high-dose buprenorphine maintenance therapy at the Fleury-Merogis (France) prison since 1996 Ann Med Interne (Paris) 152 suppl 7 2001 9 14 (in French)
25. TW Kinlock, MS Gordon, RP Schwartz, TT Fitzgerald, KE O'Grady A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease J Subst Abuse Treat 37 2009 277 285
26. FL Altice, JA Mezger, J Hodges Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication Clin Infect Dis 38 suppl 5 2004 S376 S387
27. RS Broadhead, TH Kerr, JPC Grund, FL Altice Safer injection facilities in North America: their place in public policy and health initiatives J Drug Issues 32 2002 329 355
28. RP Mattick, J Kimber, C Breen, M Davoli Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence Cochrane Database Syst Rev 2 2008 CD002207.
29. RD Bruce, FL Altice, MN Gourevitch, GH Friedland Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice J Acquir Immune Defic Syndr 41 2006 563 572
30. RA Greenstein, BD Evans, AT McLellan, CP O'Brien Predictors of favorable outcome following naltrexone treatment Drug Alcohol Depend 12 1983 173 180
31. A Roth, I Hogan, C Farren Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals J Subst Abuse Treat 14 1997 19 22
32. D Baliunas, J Rehm, H Irving, P Shuper Alcohol consumption and risk of incident human immunodeficiency virus infection: a meta-analysis Int J Public Health 55 2009 159 166
33. TW Kim, SG Kertesz, NJ Horton, N Tibbetts, JH Samet Episodic homelessness and health care utilization in a prospective cohort of HIV-infected persons with alcohol problems BMC Health Serv Res 6 2006 19
34. TW Kim, A Palepu, DM Cheng, H Libman, R Saitz, JH Samet Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems AIDS Care 19 2007 1039 1047
35. JT Parsons, E Rosof, B Mustanski Patient-related factors predicting HIV medication adherence among men and women with alcohol problems J Health Psychol 12 2007 357 370
36. JC Fisher, H Bang, SH Kapiga The association between HIV infection and alcohol use: a systematic review and meta-analysis of African studies Sex Transm Dis 34 2007 856 863
37. A Palepu, A Raj, NJ Horton, N Tibbetts, S Meli, JH Samet Substance abuse treatment and risk behaviors among HIV-infected persons with alcohol problems J Subst Abuse Treat 28 2005 3 9 (Pubitemid 40250477)
38. JH Samet, AY Walley, C Bridden Illicit drugs, alcohol, and addiction in human immunodeficiency virus Panminerva Med 49 2007 67 77
39. GM Lucas, KA Gebo, RE Chaisson, RD Moore Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic AIDS 16 2002 767 774
40. A Palepu, MW Tyndall, K Li Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy J Urban Health 80 2003 667 675
41. M Schiavini, E Angeli, A Mainini Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002 HIV Med 7 2006 331 337
42. RP Mattick, R Ali, M Auriacombe Cochrane Drugs and Alcohol Group: the development of systematic reviews of treatment outcome Alcohol Alcohol 36 2001 109 111
43. M Srisurapanont, N Jarusuraisin Opioid antagonists for alcohol dependence Cochrane Database Syst Rev 1 2005 CD001867.
44. SH Cho, WW Whang Acupuncture for alcohol dependence: a systematic review Alcohol Clin Exp Res 33 2009 1305 1313
45. BJ Mason, RL Ownby Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials CNS Spectr 5 2000 58 69
46. RF Anton, SS O'Malley, DA Ciraulo Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial JAMA 295 2006 2003 2017
47. K Mann, F Kiefer, R Spanagel, J Littleton Acamprosate: recent findings and future research directions Alcohol Clin Exp Res 32 2008 1105 1110
48. JC Garbutt The state of pharmacotherapy for the treatment of alcohol dependence J Subst Abuse Treat 36 2009 S15 S23
49. I Ferreros, B Lumbreras, I Hurtado, S Perez-Hoyos, I Hernandez-Aguado The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users Addiction 103 2008 651 659
50. T Frederick, P Burian, N Terrault Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS) AIDS Patient Care STDS 23 2009 915 923
51. AT Urbanus, TJ van de Laar, IG Stolte Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic AIDS 23 2009 F1 F7
52. HH Thein, Q Yi, GJ Dore, MD Krahn Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis AIDS 22 2008 1979 1991
53. P De, E Roy, JF Boivin, J Cox, C Morissette Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review J Viral Hepat 15 2008 279 292
54. R Weber, CA Sabin, N Friis-Moller Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study Arch Intern Med 166 2006 1632 1641
55. J Macias, JA Mira, LF Lopez-Cortes Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C Antivir Ther 11 2006 839 846
56. R Bedimo, AO Westfall, M Mugavero, H Drechsler, N Khanna, M Saag Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients HIV Med 2010 10.1111/j.1468-1293.2009.00815.x published online Feb 16.
57. B Peixoto, L Lopez, J Areias, R Cerqueira, JL Arias Executive functions in chronic hepatitis C virus-infected patients Adv Clin Exp Med 17 2008 53 60
58. L Serfaty, J Capeau Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data Liver Int 29 suppl 2 2009 13 25
59. H Izzedine, D Sene, P Cacoub Kidney diseases in HIV/HCV-co-infected patients AIDS 23 2009 1219 1226
60. JD Scott, A Wald, M Kitahata Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population AIDS Patient Care STDS 23 2009 925 929
61. AH Litwin, KA Harris, S Nahvi Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program J Subst Abuse Treat 37 2009 32 40
62. J Grebely, K Petoumenos, GV Matthews Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study Drug Alcohol Depend 107 2009 244 249
63. DS Maru, RD Bruce, S Basu, FL Altice Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations Clin Infect Dis 47 2008 952 961
64. V Soriano, E Vispo, P Labarga, J Medrano, P Barreiro Viral hepatitis and HIV co-infection Antiviral Res 85 2010 303 315
65. J Berenguer, J Alvarez-Pellicer, PM Martin Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2009 407 413
66. JE Kaplan, C Benson, KH Holmes, JT Brooks, A Pau, H Masur Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America MMWR Recomm Rep 58 2009 1 207
67. DN Podlekareva, A Mocroft, FA Post Mortality from HIV and TB coinfections is higher in eastern Europe than in western Europe and Argentina AIDS 23 2009 2485 2495
68. WHO Guidelines for surveillance of drug resistance in tuberculosis http://www.who.int/tb/publications/mdr-surveillance/en/index.html 2009 (accessed Feb 24, 2010).
69. WHO Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance, fourth global report http://www.who.int/tb/publications/2008/drs-report4-26feb08.pdf 2008 (accessed Feb 24, 2010).
70. WHO Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach http://whqlibdoc.who.int/ publications/2008/9789241596930-eng.pdf 2008 (accessed Jan 15, 2010).
71. JE Golub, J Astemborski, M Ahmed Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users J Acquir Immune Defic Syndr 49 2008 532 537
72. P Sadaphal, J Astemborski, NMH Graham Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis Clin Infect Dis 33 2001 1687 1691
73. SD Lawn, AD Harries, R Wood Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings Curr Opin HIV AIDS 5 2009 18 26
74. Samandari T, Mosimaneotsile B, Agizew T, et al. Randomized, placebo-controlled trial of 6 vs 36 months isoniazid TB preventive therapy for HIV-infected adults in Botswana. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 16-19, 2010. Abstract 104LB.
75. WHO Tuberculosis infection control in the era of expanding HIV care and treatment. Addendum to WHO guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings http://www.who.int/tb/ publications/who-tb-99-269/en/index.html 2007 (accessed Jan 15, 2009).
76. WHO WHO policy on TB infection control in health-care facilities, congregate settings and households http://whqlibdoc.who.int/publications/2009/ 9789241598323-eng.pdf 2009 (accessed Feb 24, 2010).
77. L Sylla, RD Bruce, A Kamarulzaman, FL Altice Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services Int J Drug Policy 18 2007 306 312
78. SS Abdool-Karim, K Naidoo, A Grobler Timing of initiation of antiretroviral drugs during tuberculosis therapy N Engl J Med 362 2010 697 706
79. WHO Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents http://www.who.int/hiv/pub/arv/advice/en/ 2009 (accessed Feb 24, 2010).
80. R Kohli, Y Lo, AA Howard Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy Clin Infect Dis 41 2005 864 872
81. V Hope, J Kimber, P Vickerman, M Hickman, F Ncube Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England BMC Infect Dis 8 2008 120
82. N Crum-Cianflone, J Weekes, M Bavaro Recurrent community-associated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors AIDS Patient Care STDS 23 2009 499 502
83. MD Burkey, LE Wilson, RD Moore, GM Lucas, J Francis, KA Gebo The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era HIV Med 9 2008 858 862
84. MP Reyes, A Ali, RE Mendes, DJ Biedenbach Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008 Medicine (Baltimore) 88 2009 294 301
85. J Barry, M Ward, S Cotter Botulism in injecting drug users, Dublin, Ireland, November-December 2008 Euro Surveill 14 2009 pii=19082.
86. K Murray-Lillibridge, J Barry, S Reagan Epidemiological findings and medical, legal, and public health challenges of an investigation of severe soft tissue infections and deaths among injecting drug users - Ireland, 2000 Epidemiol Infect 134 2006 894 901
87. BW Frazee, C Fee, J Lynn Community-acquired necrotizing soft tissue infections: a review of 122 cases presenting to a single emergency department over 12 years J Emerg Med 34 2008 139 146
88. YH Hsieh, RE Rothman, JG Bartlett, S Yang, GD Kelen HIV seropositivity predicts longer duration of stay and rehospitalization among nonbacteremic febrile injection drug users with skin and soft tissue infections J Acquir Immune Defic Syndr 49 2008 398 405
89. ML Fernandez Guerrero, JJ Gonzalez Lopez, A Goyenechea, J Fraile, M de Gorgolas Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome Medicine (Baltimore) 88 2009 1 22
90. SJ Curtis, A Tanna, HH Russell Invasive group A streptococcal infection in injecting drug users and non-drug users in a single UK city J Infect 54 2007 422 426
91. JM Sierra, F Sanchez, P Castro Group A streptococcal infections in injection drug users in Barcelona, Spain: epidemiologic, clinical, and microbiologic analysis of 3 clusters of cases from 2000 to 2003 Medicine (Baltimore) 85 2006 139 146
92. TA Takahashi, ML Maciejewski, K Bradley US hospitalizations and costs for illicit drug users with soft tissue infections J Behav Health Serv Res 2009 10.1007/s11414-009-9177-z published online April 21.
93. IA Binswanger, TA Takahashi, K Bradley, TH Dellit, KL Benton, JO Merrill Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death J Stud Alcohol Drugs 69 2008 924 932
94. R Kohli, Y Lo, P Homel Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study Clin Infect Dis 43 2006 90 98
95. ML Nguyen, KJ Farrell, CJ Gunthel Non-AIDS-defining malignancies in patients with HIV in the HAART era Current Infect Dis Rep 12 2009 46 55
96. D:A:D Study Group Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration Lancet 371 2008 1417 1426
97. MM Zahari, W Hwan Bae, NZ Zainal, H Habil, A Kamarulzaman, FL Altice Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia Am J Drug Alcohol Abuse 36 2010 31 38
98. SC Kalichman, D Rompa HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy Sex Transm Infect 79 2003 59 61
99. P Anand, SA Springer, MM Copenhaver, FL Altice Neurocognitive impairment and HIV risk factors: a reciprocal relationship AIDS Behav 2010 10.1007/s10461-010-9684-1 published online March 16.
100. RE Chaisson, GL Barnes, J Hackman A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users Am J Med 110 2001 610 615
101. SL Batki, VA Gruber, JM Bradley, M Bradley, K Delucchi A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users Drug Alcohol Depend 66 2002 283 293
102. GE Macalino, JW Hogan, JA Mitty A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users AIDS 21 2007 1473 1477
103. FL Altice, DS Maru, RD Bruce, SA Springer, GH Friedland Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial Clin Infect Dis 45 2007 770 778
104. DS Maru, RD Bruce, M Walton, SA Springer, FL Altice Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial J Acquir Immune Defic Syndr 50 2009 176 181
105. Arnsten JH, Berg KM, Mouriz J, Li X, Goldberg U, Goldstein H. Final results from a 6-month, randomized controlled trial of directly observed therapy delivered in methadone clinics. Fourth International Conference on HIV Treatment Adherence; Miami, FL, USA; April 5-7, 2009. Abstract 030.
106. GM Lucas, BA Mullen, PJ Weidle, S Hader, ME McCaul, RD Moore Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups Clin Infect Dis 42 2006 1628 1635
107. GM Lucas, PJ Weidle, S Hader, RD Moore Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study Clin Infect Dis 38 suppl 5 2004 S409 S413
108. JL Sorensen, NA Haug, KL Delucchi Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial Drug Alcohol Depend 88 2007 54 63
109. JP Moatti, MP Carrieri, B Spire, JA Gastaut, JP Cassuto, J Moreau Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group AIDS 14 2000 151 155
110. DW Purcell, MH Latka, LR Metsch Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users J Acquir Immune Defic Syndr 46 suppl 2 2007 S35 S47
111. SK Avants, A Margolin, M Copenhaver, MH Usubiaga, C Doebrick Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy J Subst Abuse Treat 26 2004 67 78
112. A Margolin, SK Avants, LA Warburton, KA Hawkins, J Shi A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users Health Psychol 22 2003 223 228
113. SC Kalichman, J Cherry, D Cain Nurse-delivered antiretroviral treatment adherence intervention for people with low literacy skills and living with HIV/AIDS J Assoc Nurses AIDS Care 16 2005 3 15
114. ML Petersen, Y Wang, MJ van der Laan, D Guzman, E Riley, DR Bangsberg Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis Clin Infect Dis 45 2007 908 915
115. FL Altice, S Springer, M Buitrago, DP Hunt, GH Friedland Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users J Urban Health 80 2003 416 427
116. C Goujard, N Bernard, N Sohier Impact of a patient education program on adherence to HIV medication: a randomized clinical trial J Acquir Immune Defic Syndr 34 2003 191 194
117. RS Broadhead, DD Heckathorn, FL Altice Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study Soc Sci Med 55 2002 235 246
118. JM Simoni, DW Pantalone, MD Plummer, B Huang A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women Health Psychol 26 2007 488 495
119. MK Rawlings, MA Thompson, CF Farthing Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients J Acquir Immune Defic Syndr 34 2003 174 183
120. JT Parsons, SA Golub, E Rosof, C Holder Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial J Acquir Immune Defic Syndr 46 2007 443 450
121. SF Morin, MA Chesney, AA Ehrhardt Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: The Healthy Living Project randomized controlled study J Acquir Immune Defic Syndr 44 2007 213 221
122. RE Rogers, ST Higgins, K Silverman Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers Psychol Addict Behav 22 2008 544 550
123. JL Sindelar, TA Olmstead, JM Peirce Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs Addiction 102 2007 1463 1471
124. CP Chaulk, VA Kazandjian Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel JAMA 279 1998 943 948
125. J Volmink, P Garner Directly observed therapy for treating tuberculosis Cochrane Database Syst Rev 4 2007 CD003343.
126. GM Lucas, CW Flexner, RD Moore Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDS 16 2002 527 535
127. N Ford, JB Nachega, ME Engel, EJ Mills Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials Lancet 374 2009 2064 2071
128. JE Hart, CY Jeon, LC Ivers Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review J Acquir Immune Defic Syndr 54 2010 167 179
129. HL Behforouz, A Kalmus, CS Scherz, JS Kahn, MB Kadakia, PE Farmer Directly observed therapy for HIV antiretroviral therapy in an urban US setting J Acquir Immune Defic Syndr 36 2004 642 645
130. B Conway, J Prasad, R Reynolds Directly observed therapy for the management of HIV-infected patients in a methadone program Clin Infect Dis 38 suppl 5 2004 S402 S408
131. CG Mitchell, S Freels, CM Creticos, A Oltean, R Douglas Preliminary findings of an intervention integrating modified directly observed therapy and risk reduction counseling AIDS Care 19 2007 561 564
132. JA Mitty, GE Macalino, LB Bazerman The use of community-based modified directly observed therapy for the treatment of HIV-infected persons J Acquir Immune Defic Syndr 39 2005 545 550
133. WHO United Nations Office on Drug and Crime UNAIDS Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper http://www.unodc.org/docs/treatment/Brochure-E.pdf 2004 (accessed Jan 15, 2009).
134. A Palepu, MW Tyndall, R Joy Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy Drug Alcohol Depend 84 2006 188 194
135. P Roux, MP Carrieri, J Cohen Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment Clin Infect Dis 49 2009 1433 1440
136. GM Lucas, A Chaudhry, J Hsu Clinic-based treatment of opioid dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial Ann Intern Med 152 2010 704 711
137. DP Kidder, RJ Wolitski, S Royal Access to housing as a structural intervention for homeless and unstably housed people living with HIV: rationale, methods, and implementation of the housing and health study AIDS Behav 11 suppl 6 2007 149 161
138. D Smith-Rohrberg, J Mezger, M Walton, RD Bruce, FL Altice Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users J Acquir Immune Defic Syndr 43 suppl 1 2006 S48 S53
139. MB Kushel, G Colfax, K Ragland, A Heineman, H Palacio, DR Bangsberg Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection Clin Infect Dis 43 2006 234 242
140. AR Wohl, WH Garland, R Valencia A randomized trial of directly administered antiretroviral therapy and adherence case management intervention Clin Infect Dis 42 2006 1619 1627
141. D Smith-Rohrberg, FL Altice Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach Clin Infect Dis 43 2006 1221 1222
142. FL Altice, SA Springer DAART for human immunodeficiency virus-infected patients: studying subjects not at risk for nonadherence and use of untested interventions Arch Intern Med 170 2010 109 110
143. MR Weaver, CJ Conover, RJ Proescholdbell Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders J Ment Health Policy Econ 12 2009 33 46
144. MN Gourevitch, P Chatterji, N Deb, EE Schoenbaum, BJ Turner On-site medical care in methadone maintenance: associations with health care use and expenditures J Subst Abuse Treat 32 2007 143 151
145. S Lertmaharit, P Kamol-Ratankul, H Sawert, S Jittimanee, S Wangmanee Factors associated with compliance among tuberculosis patients in Thailand J Med Assoc Thai 88 suppl 4 2005 S149 S156
146. TM Hammett HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response Am J Public Health 96 2006 974 978
147. DS-R Maru, S Basu, FL Altice HIV control efforts should directly address incarceration Lancet Infect Dis 7 2007 568 569
148. SA Springer, FL Altice Managing HIV/AIDS in correctional settings Curr HIV/AIDS Rep 2 2005 165 170
149. R Wallace Social disintegration and the spread of AIDS - II. Meltdown of sociogeographic structure in urban minority neighborhoods Soc Sci Med 37 1993 887 896
150. JC Thomas From slavery to incarceration: social forces affecting the epidemiology of sexually transmitted diseases in the rural South Sex Transm Dis 33 suppl 7 2006 S6 10
151. AA Adimora, VJ Schoenbach, AA Adimora, VJ Schoenbach Social context, sexual networks, and racial disparities in rates of sexually transmitted infections J Infect Dis 191 suppl 1 2005 S115 S122
152. LD Harrison, LD Harrison The revolving prison door for drug-involved off enders: challenges and opportunities Crime Delinq 47 2001 462 485
153. SA Springer, E Pesanti, J Hodges, T Macura, G Doros, FL Altice Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community Clin Infect Dis 38 2004 1754 1760
154. LM Maruschak, R Beaver HIV in prisons, 2008 December, 2009 US Department of Justice Washington, DC Report no. NCJ 228307.
155. S Babudieri, A Aceti, GP D'Offizi, S Carbonara, G Starnini Directly observed therapy to treat HIV infection in prisoners JAMA 284 2000 179 180
156. JM Soto Blanco, IR Perez, JC March Adherence to antiretroviral therapy among HIV-infected prison inmates (Spain) Int J STD AIDS 16 2005 133 138
157. BL Stephenson, DA Wohl, CE Golin, HC Tien, P Stewart, AH Kaplan Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals Public Health Rep 120 2005 84 88
158. A Palepu, MW Tyndall, K Chan, E Wood, JS Montaner, RS Hogg Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes Antivir Ther 9 2004 713 719
159. S Larney, K Dolan A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res 15 2009 107 112
160. SA Springer, S Chen, FL Altice Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment J Urban Health 2010 10.1007/s11524-010-9438-4 published online Feb 23.
161. D Smith-Rohrberg, RD Bruce, FL Altice Review of corrections-based therapy for opiate-dependent patients: implications for buprenorphine treatment among correctional populations J Drug Issues 34 2004 451 480
162. T Kerr, A Marshall, J Walsh Determinants of HAART discontinuation among injection drug users AIDS Care 17 2005 539 549 (Pubitemid 40979462)
163. T Rodrigo, JA Cayla, P Garcia de Olalla Effectiveness of tuberculosis control programmes in prisons, Barcelona 1987-2000 Int J Tuberc Lung Dis 6 2002 1091 1097
164. D McVay, V Schiraldi, J Ziedenberg Treatment or incarceration? National and state findings on the efficacy and cost savings of drug treatment versus imprisonment 2004 Justice Policy Institute Washington, DC
165. C Chandler, G Patton, J Job Community-based alternative sentencing for HIV-positive women in the Criminal Justice System Berkeley Womens Law J 14 1999 66 69
166. E Drucker Population impact of mass incarceration under New York's Rockefeller drug laws: an analysis of years of life lost J Urban Health 79 2002 434 435